Table 4.

Indication for SGLT2 inhibitors according to the eligibility criteria of the two major HF SGLT2 inhibitor trials

	Total CHECK‐HF population	Diabetics	Non‐diabetics
DAPA‐HF trial a
Eligible	742 (31.3)	184 (25.4)	558 (33.8)
Not eligible	1632 (68.7)	539 (74.6)	1093 (66.2)
EMPEROR‐Reduced trial a
Eligible	571 (24.1)	175 (24.2)	396 (24.0)
Not eligible	1801 (75.9)	547 (75.8)	1254 (76.0)

HF, heart failure; SGLT2, sodium–glucose cotransporter 2.

^a Eligibility criteria are shown in Supporting Information, Table S2 .